Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript
Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.25. Aytu BioPharma, Inc.
Aytu Biopharma Inc (AYTU)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 1,086,812 | $3,086,546 | 0.18% | |
| 2. | Stonepine Capital Timothy P. Lynch | 472,469 | $1,341,812 | +1% | 0.58% |
| 3. | 81,628 | $231,824 | 0% | ||
| 4. | Renaissance Technologies Jim Simons | 68,923 | $196,000 | +14% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.87 | 12,000 | 21,935 | 2023-06-16 | Filing | ||
| $1.86 | 14,000 | 71,591 | 2023-06-14 | Filing | ||
| $0.22 | 112,371 | Officer, Director | 1,231,877 | 2022-12-19 | Filing | |
| $0.24 | 100,000 | Officer | 182,056 | 2022-12-19 | Filing | |
| $0.23 | 90,000 | Officer | 190,000 | 2022-11-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 0 | Director | 0 | 2020-04-27 | Filing | |
| $1.82 | 5,108,921 | Director | 0 | 2020-04-27 | Filing | |
| $1.55 | 92,777 | Large Shareholder | 9,713,068 | 2020-04-15 | Filing | |
| $0.00 | 0 | Director | 1 | 2020-03-10 | Filing | |
| $0.99 | 2,456,822 | Director | 1 | 2020-03-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 33,046 | $93,882 | 0% | |
| 2. | 27,251 | $77,393 | 0% | |
| 3. | 22,793 | $64,732 | 0% | |
| 4. | 14,568 | $41,373 | 0% | |
| 5. | 13,882 | $39,425 | 0% |
News See All
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript
Robert Blum: Good afternoon, everyone, and thank you for joining us for Aytu BioPharma's Fiscal 2024 First Quarter Financial Results Conference Call for the period ended September 30, 2023.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript
Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2023 Earnings Call Transcript
Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q3 Results Conference Call. At this time, all participants are in a listen-only mode.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2023 Earnings Call Transcript
Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q2 Results Conference Call. At this time, all participants are on a listen-only mode. . Please note this conference is being recorded.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Aytu BioPharma Fiscal 2023 Q1 Results Call.
Where Do Hedge Funds Stand On Aytu BioScience, Inc. (AYTU)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Is Aytu BioScience, Inc. (AYTU) A Good Stock To Buy?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Are Warming Up To Aytu BioScience, Inc. (AYTU)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much.
Billionaire Hedge Funds
